Table 1.

Expression of CD137 and IL-13 in HL tumor microarray determined by immunohistochemical double staining. For CD137: + at least 5 cells, ++ at least 10 cells, +++ more than 15 cells stained in the section. For IL-13 staining: + at least 10%, ++ at least 30% and +++ more than 50% of the section stained.

Number	Case	CD137	IL-13	Diagnosis
1	A1	+	++	−
2	A2	+	+	Nodular sclerosis
3	A3	−	+++	Mixed cellularity
4	A4	−	++	Nodular sclerosis
5	A5	−	+	Mixed cellularity
6	A6	+	+	Mixed cellularity
7	A7	++	++	Mixed cellularity
8	A8	−	+++	Mixed cellularity
9	B1	+	+	Mixed cellularity
10	B2	+	−	Lymphocyte predominant
11	B3	−	+	Nodular sclerosis
12	B4	+++	+++	Mixed cellularity
13	B5	+++	++	Mixed cellularity
14	B6	+++	++	Lymphocyte predominant
15	B7	++	+++	Lymphocyte predominant
16	B8	+++	+++	Mixed cellularity
17	C1	+	+	−
18	C2	−	−	Mixed cellularity
19	C3	−	+	Mixed cellularity
20	C4	+	++	Mixed cellularity
21	C5	+	+	Mixed cellularity
22	C6	−	++	Mixed cellularity
23	C7	++	+++	Mixed cellularity
24	C8	++	+++	−
25	D1	+	−	Lymphocyte predominant
26	D2	+++	−	Lymphocyte predominant
27	D3	+	+	Lymphocyte predominant
28	D4	+	++	Lymphocyte predominant
29	D5	+	+++	Lymphocyte predominant
30	D6	++	+++	Nodular sclerosis
31	D7	+++	+++	−
32	D8	++	+++	Mixed cellularity
33	E1	+	+	Lymphocyte predominant
34	E2	+	+	Mixed cellularity
35	E3	−	+	Mixed cellularity
36	E4	−	++	Nodular sclerosis
37	E5	−	−	Mixed cellularity
38	E6	+	++	Mixed cellularity
39	E7	−	+	Lymphocyte predominant
40	E8	+	+++	Nodular sclerosis
41	F1	−	+	Mixed cellularity
42	F2	−	−	Lymphocyte predominant
43	F3	−	−	Mixed cellularity
44	F4	++	+	Nodular sclerosis
45	F5	−	+	Nodular sclerosis
46	F6	−	++	Nodular sclerosis
47	F7	++	++	Lymphocyte depletion
48	F8	+	++	Lymphocyte depletion